Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Brilaroxazine
2. 1239729-06-6
3. X8l60ba01i
4. 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo[b][1,4]oxazin-3(4h)-one
5. 2h-1,4-benzoxazin-3(4h)-one, 6-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-
6. 2h-1,4-benzoxazin-3(4h)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-
7. 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo(b)(1,4)oxazin-3(4h)-one
8. Brilaroxazin
9. Brilaroxazine [inn]
10. Unii-x8l60ba01i
11. Brilaroxazine [who-dd]
12. Schembl3404085
13. Bdbm312188
14. Dtxsid001136921
15. Db09226
16. Rp-5063
17. Us9604944, 15b (example 14)
18. Hy-109112
19. Cs-0077721
20. 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-2h-1,4-benzoxazin-3(4h)-one
21. 6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4h-1,4-benzoxazin-3-one
22. 2036070-48-9
| Molecular Weight | 450.4 g/mol |
|---|---|
| Molecular Formula | C22H25Cl2N3O3 |
| XLogP3 | 4.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Exact Mass | 449.1272971 g/mol |
| Monoisotopic Mass | 449.1272971 g/mol |
| Topological Polar Surface Area | 54 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 562 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for the treatment of schizophrenia and schizoaffective disorder.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Brilaroxazine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Brilaroxazine, including repackagers and relabelers. The FDA regulates Brilaroxazine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Brilaroxazine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Brilaroxazine supplier is an individual or a company that provides Brilaroxazine active pharmaceutical ingredient (API) or Brilaroxazine finished formulations upon request. The Brilaroxazine suppliers may include Brilaroxazine API manufacturers, exporters, distributors and traders.
Brilaroxazine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Brilaroxazine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Brilaroxazine GMP manufacturer or Brilaroxazine GMP API supplier for your needs.
A Brilaroxazine CoA (Certificate of Analysis) is a formal document that attests to Brilaroxazine's compliance with Brilaroxazine specifications and serves as a tool for batch-level quality control.
Brilaroxazine CoA mostly includes findings from lab analyses of a specific batch. For each Brilaroxazine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Brilaroxazine may be tested according to a variety of international standards, such as European Pharmacopoeia (Brilaroxazine EP), Brilaroxazine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Brilaroxazine USP).
LOOKING FOR A SUPPLIER?
